Excellent share price performance and I admit I sold close to the bottom after years of frustration although did buy 3NVDL on Jan 2nd which is a 3x Nvidia Leveraged ETF so have done extremely well there. I will put some of my profits back into Hutchmed shortly. |
There does appear to be a growing number of analysts expecting an earnings beat creating an expectation of rising share price |
I am not sure these moves on no news really mean anything…and could well be reversed tomorrow when the market takes fright at some statement coming from US/China that indicates more restrictions.
The next news I will be looking for will be from Takeda…
Their annual results are due in early/mid May and will contain the $15m sales from 2023 disclosed by HCM and the first three months of 2024.
There may have been some stocking within the $15m and conversion of those on early access programs, but I hope they can sell $30m in Q1 and build to a $50m/quarter during 2024. This would give US in market sales of $150-180 and a $20m royalty (pure profit) to HCM (plus manufacturing fees).
It was interesting to see in the company presentation that Europe is potentially a much larger market than the US. It did not appear that the EMA was giving priority status, so they may take longer than the US to approve…that will also be good news when it comes. |
Nice move today. Wish it would continue and some decent news would appear to maintain it! Can dream ;-) |
fantastic results, great progress, one day they may attract a decent valuation; maybe that will be when they start generating free cashflow, but hopefully before that! |
I have stuck with HCM through everything because in the end the story has not changed.
Management has been ropey at times, but they are delivering the products and the cash is now coming in.
Only politics holding them back and they are working their way round that. |
Good results.Little to worry about other than the geopolitically afflicted rating! |
Revenue grew 97%...Strengthened cash balance, with $886.3 million at year end (2022: $631.0m) |
Results tomorrow. |
Looking a bit better. Did we all get a response to emails sent to the co? |
AZ reporting $44m of orpathys sales.
This would imply $30m revenue for HCM as flat on H1. |
I know what you mean NoS, having recently semi-retired….fortunately I don’t have to access my holding here for some time…and I have the option of selling in chunks to give to my kids to put into their LISA…..this company still has a lot to give in the next 10-20 years.
As today’s 10% rise shows this can move quickly upwards…but as we know quickly down too…it is barely believable that all the gain associated with the Takeda deal and FDA approval has evaporated. |
thankyou 1jat, I do think that I will be buying at some stage, possibly later this year if or when the geo-politics issues subside. This is such a great under valued Company. My specific issue is one of oppoertunity cost here and my problem of effectively dead money and I have a specific timeframe to grow my investment and frankly time will run out! |
More positive news yesterday and no positive impact on the share price. HCM really are in a rut at the moment. Thought 2024 was going to be better, but still 11 months to go. |
NoS
I for one will continue to value your thoughts…..as a long term follower of HCM I expect you will keep an eye on it, in case there is a change of tone and fortune - I also expect you will buy back in at some point…
Good luck with your new investments….tell us what you select. |
Bareknee - Bitter posts just make it look like you're continually trying to validate your reasons for selling.
Not at all, I was stating the facts as I see them.. |
Let it go DaveyNerd. For better or worse you've sold up.
Bitter posts just make it look like you're continually trying to validate your reasons for selling. It's like the reverse of the Quindell situation was for you.
Live, learn and move on, but don't give up the day job ! |
Agree Lauders; to not engage with shareholders and do absolutely nothing given the recent decline, does just smack of apathy, and comes across as a little feeble. |
It has been stated they don't really "care" about their shareholders mcmather. I suppose your point sort of confirms this, unfortunately. |
Shame there wasn't an update of sorts:
"HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT)." |
Bleak viewing the decline over the last 12 months |
and the share price falls again as usual |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
